Top

Published in:

01-12-2013 | Prevention of Heart Failure (M St. John Sutton, Section Editor)

Heart Failure and Tachycardia-Induced Cardiomyopathy

Authors: Ethan R. Ellis, Mark E. Josephson

Published in: Current Heart Failure Reports | Issue 4/2013

Abstract

Congestive heart failure is a major health care concern affecting almost six million Americans and an estimated 23 million people worldwide, and its prevalence is increasing with time. Long-standing tachycardia is a well-recognized cause of heart failure and left ventricular dysfunction and has led to the nomenclature, tachycardia-induced cardiomyopathy. Tachycardia-induced cardiomyopathy is generally a reversible cardiomyopathy with effective treatment of the causative arrhythmia, either with medications, surgery, or catheter ablation. Tachycardia-induced cardiomyopathy remains poorly understood and is likely under-diagnosed. A better understanding of tachycardia-induced cardiomyopathy and improved recognition of its presence in clinical practice is vital to the health of patients with this disorder. The goal of this review is to discuss the pathogenesis and clinical manifestations of tachycardia-induced cardiomyopathy, as well as approaches to its diagnosis and treatment.

Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.PubMedCrossRef

McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39:60–9.PubMedCrossRef

Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Progr Cardiovasc Dis. 2005;47:320–32.CrossRef

Gossage AM, Braxton Hicks J. On auricular fibrillation. QJM 1913:435–40.

Coleman 3rd HN, Taylor RR, Pool PE, et al. Congestive heart failure following chronic tachycardia. Am Heart J. 1971;81:790–8.PubMedCrossRef

Armstrong PW, Stopps TP, Ford SE, de Bold AJ. Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. Circulation. 1986;74:1075–84.PubMedCrossRef

Wilson JR, Douglas P, Hickey WF, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation. 1987;75:857–67.PubMedCrossRef

Scott BD, Sharma MK, Levett JM, et al. Cardiac geometry and mass changes associated with pacing-induced cardiomyopathy in the dog. Am Heart J. 1993;125:1047–53.PubMedCrossRef

Spinale FG, Hendrick DA, Crawford FA, Smith AC, Hamada Y, Carabello BA. Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am J Physiol. 1990;259:H218–29.PubMed

10.

Thackray SD, Witte KK, Nikitin NP, Clark AL, Kaye GC, Cleland JG. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J. 2003;24:1143–52.PubMedCrossRef

11.

Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288:3115–23.PubMedCrossRef

12.

Gardiwal A, Yu H, Oswald H, et al. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator. Europace. 2008;10:358–63.PubMedCrossRef

13.

Delgado V, Tops LF, Trines SA, et al. Acute effects of right ventricular apical pacing on left ventricular synchrony and mechanics. Circ Arrhythmia Electrophysiol. 2009;2:135–45.CrossRef

14.

Lee SJ, McCulloch C, Mangat I, Foster E, De Marco T, Saxon LA. Isolated bundle branch block and left ventricular dysfunction. J Card Fail. 2003;9:87–92.PubMedCrossRef

15.

Blanc JJ, Fatemi M, Bertault V, Baraket F, Etienne Y. Evaluation of left bundle branch block as a reversible cause of non-ischaemic dilated cardiomyopathy with severe heart failure. A new concept of left ventricular dyssynchrony-induced cardiomyopathy. Europace. 2005;7:604–10.PubMedCrossRef

16.

ten Cate FE U, Kruessell MA, Wagner K, et al. Dilated cardiomyopathy in children with ventricular preexcitation: the location of the accessory pathway is predictive of this association. J Electrocardiol. 2010;43:146–54.CrossRef

17.

Cadrin-Tourigny J, Fournier A, Andelfinger G, Khairy P. Severe left ventricular dysfunction in infants with ventricular preexcitation. Heart Rhythm. 2008;5:1320–2.PubMedCrossRef

18.

Howard RJ, Moe GW, Armstrong PW. Sequential echocardiographic-Doppler assessment of left ventricular remodelling and mitral regurgitation during evolving experimental heart failure. Cardiovasc Res. 1991;25:468–74.PubMedCrossRef

19.

Shannon RP, Komamura K, Stambler BS, Bigaud M, Manders WT, Vatner SF. Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. Am J Physiol. 1991;260:H1903–11.PubMed

20.

Ohno M, Cheng CP, Little WC. Mechanism of altered patterns of left ventricular filling during the development of congestive heart failure. Circulation. 1994;89:2241–50.PubMedCrossRef

21.

Howard RJ, Stopps TP, Moe GW, Gotlieb A, Armstrong PW. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol. 1988;66:1505–12.PubMedCrossRef

22.

Morgan DE, Tomlinson CW, Qayumi AK, Toleikis PM, McConville B, Jamieson WR. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol. 1989;14:489–95. discussion 96–8.PubMedCrossRef

23.

O'Brien PJ, Ianuzzo CD, Moe GW, Stopps TP, Armstrong PW. Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. Can J Physiol Pharmacol. 1990;68:34–9.PubMedCrossRef

24.

Moe GW, Stopps TP, Howard RJ, Armstrong PW. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. J Lab Clin Med. 1988;112:426–32.PubMed

25.

Tanaka R, Spinale FG, Crawford FA, Zile MR. Effect of chronic supraventricular tachycardia on left ventricular function and structure in newborn pigs. J Am Coll Cardiol. 1992;20:1650–60.PubMedCrossRef

26.

Moe GW, Angus C, Howard RJ, Parker TG, Armstrong PW. Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. Cardiovasc Res. 1992;26:362–6.PubMedCrossRef

27.

Tibayan FA, Lai DT, Timek TA, et al. Alterations in left ventricular torsion in tachycardia-induced dilated cardiomyopathy. J Thorac Cardiovasc Surg. 2002;124:43–9.PubMedCrossRef

28.

Damiano Jr RJ, Tripp Jr HF, Asano T, Small KW, Jones RH, Lowe JE. Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia. J Thorac Cardiovasc Surg. 1987;94:135–43.PubMed

29.

Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261:H308–18.PubMed

30.

Riegger AJ, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin Sci (Lond). 1982;62:465–9.

31.

Moe GW, Stopps TP, Angus C, Forster C, De Bold AJ, Armstrong PW. Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. J Am Coll Cardiol. 1989;13:173–9.PubMedCrossRef

32.

Spinale FG, Clayton C, Tanaka R, et al. Myocardial Na+, K(+)-ATPase in tachycardia induced cardiomyopathy. J Mol Cell Cardiol. 1992;24:277–94.PubMedCrossRef

33.

Qin F, Shite J, Mao W, Liang CS. Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur J Pharmacol. 2003;461:149–58.PubMedCrossRef

34.

Shite J, Qin F, Mao W, Kawai H, Stevens SY, Liang C. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol. 2001;38:1734–40.PubMedCrossRef

35.

Spinale FG, Grine RC, Tempel GE, Crawford FA, Zile MR. Alterations in the myocardial capillary vasculature accompany tachycardia-induced cardiomyopathy. Basic Res Cardiol. 1992;87:65–79.PubMedCrossRef

36.

Shannon RP, Komamura K, Shen YT, Bishop SP, Vatner SF. Impaired regional subendocardial coronary flow reserve in conscious dogs with pacing-induced heart failure. Am J Physiol. 1993;265:H801–9.PubMed

37.

Calderone A, Bouvier M, Li K, Juneau C, de Champlain J, Rouleau JL. Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. Circ Res. 1991;69:332–43.PubMedCrossRef

38.

Marzo KP, Frey MJ, Wilson JR, et al. Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing. Circ Res. 1991;69:1546–56.PubMedCrossRef

39.

Yonemochi H, Yasunaga S, Teshima Y, et al. Rapid electrical stimulation of contraction reduces the density of beta-adrenergic receptors and responsiveness of cultured neonatal rat cardiomyocytes. Possible involvement of microtubule disassembly secondary to mechanical stress. Circulation. 2000;101:2625–30.PubMedCrossRef

40.

Omichi C, Tanaka T, Kakizawa Y, et al. Improvement of cardiac function and neurological remodeling in a patient with tachycardia-induced cardiomyopathy after catheter ablation. J Cardiol. 2009;54:134–8.PubMedCrossRef

41.

Perreault CL, Shannon RP, Komamura K, Vatner SF, Morgan JP. Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing-induced heart failure. J Clin Investig. 1992;89:932–8.PubMedCrossRef

42.

Yamamoto K, Burnett Jr JC, Meyer LM, Sinclair L, Stevens TL, Redfield MM. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol. 1996;271:R1529–34.PubMed

43.

Spinale FG, Holzgrefe HH, Mukherjee R, et al. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol. 1995;268:H836–47.PubMed

44.

Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation. 1991;83:635–44.PubMedCrossRef

45.

Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29:709–15.PubMedCrossRef

46.

Krapp M, Gembruch U, Baumann P. Venous blood flow pattern suggesting tachycardia-induced 'cardiomyopathy' in the fetus. Ultrasound Obstet Gynecol. 1997;10:32–40.PubMedCrossRef

47.

Dhala A, Thomas JP. Images in cardiovascular medicine. Reversible tachycardia-induced cardiomyopathy. Circulation. 1997;95:2327–8.PubMedCrossRef

48.

Sanchez C, Benito F, Moreno F. Reversibility of tachycardia-induced cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia in infants. Br Heart J. 1995;74:332–3.PubMedCrossRef

49.

De Giovanni JV, Dindar A, Griffith MJ, et al. Recovery pattern of left ventricular dysfunction following radiofrequency ablation of incessant supraventricular tachycardia in infants and children. Heart. 1998;79:588–92.PubMed

50.

Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359–64.PubMedCrossRef

51.

Van Gelder IC, Crijns HJ, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 1993;72:560–6.PubMedCrossRef

52.

Twidale N, Sutton K, Bartlett L, et al. Effects on cardiac performance of atrioventricular node catheter ablation using radiofrequency current for drug-refractory atrial arrhythmias. Pacing Clin Electrophysiol. 1993;16:1275–84.PubMedCrossRef

53.

Heinz G, Siostrzonek P, Kreiner G, Gossinger H. Improvement in left ventricular systolic function after successful radiofrequency His bundle ablation for drug refractory, chronic atrial fibrillation and recurrent atrial flutter. Am J Cardiol. 1992;69:489–92.PubMedCrossRef

54.

Manolis AG, Katsivas AG, Lazaris EE, Vassilopoulos CV, Louvros NE. Ventricular performance and quality of life in patients who underwent radiofrequency AV junction ablation and permanent pacemaker implantation due to medically refractory atrial tachyarrhythmias. J Intervent Card Electrophysiol. 1998;2:71–6.CrossRef

55.

Redfield MM, Kay GN, Jenkins LS, Mianulli M, Jensen DN, Ellenbogen KA. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc. 2000;75:790–5.PubMedCrossRef

56.

Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. Am J Cardiol. 1994;74:242–6.PubMedCrossRef

57.

Natale A, Zimerman L, Tomassoni G, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol. 1996;78:1431–3.PubMedCrossRef

58.

• Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:9–14. This is a single center study reporting outcomes for patients with atrial fibrillation and depressed left ventricular function following catheter ablation.PubMedCrossRef

59.

• Pizzale S, Lemery R, Green MS, Gollob MH, Tang AS, Birnie DH. Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter. Can J Cardiol. 2009;25:469–72. This is a recent single center study reporting the incidence and outcomes of patients with tachycardia-induced cardiomyopathy secondary to atrial flutter.PubMedCrossRef

60.

Scheinman MM, Basu D, Hollenberg M. Electrophysiologic studies in patients with persistent atrial tachycardia. Circulation. 1974;50:266–73.PubMedCrossRef

61.

Bertil Olsson S, Blomstrom P, Sabel KG, William-Olsson G. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol. 1984;53:1465–6.PubMedCrossRef

62.

Gillette PC, Smith RT, Garson Jr A, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA. 1985;253:391–2.PubMedCrossRef

63.

Gillette PC, Wampler DG, Garson Jr A, Zinner A, Ott D, Cooley D. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol. 1985;6:405–9.PubMedCrossRef

64.

Cruz FE, Cheriex EC, Smeets JL, et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol. 1990;16:739–44.PubMedCrossRef

65.

Chiladakis JA, Vassilikos VP, Maounis TN, Cokkinos DV, Manolis AS. Successful radiofrequency catheter ablation of automatic atrial tachycardia with regression of the cardiomyopathy picture. Pacing Clin Electrophysiol. 1997;20:953–9.PubMedCrossRef

66.

• Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53:1791–7. This is a recent single center study reporting the incidence and long-term outcomes of patients with tachycardia-induced cardiomyopathy secondary to incessant atrial tachycardia.PubMedCrossRef

67.

Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57:563–70.PubMedCrossRef

68.

Fishberger SB, Colan SD, Saul JP, Mayer Jr JE, Walsh EP. Myocardial mechanics before and after ablation of chronic tachycardia. Pacing Clin Electrophysiol. 1996;19:42–9.PubMedCrossRef

69.

Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol. 1998;21:2073–8.PubMedCrossRef

70.

Corey WA, Markel ML, Hoit BD, Walsh RA. Regression of a dilated cardiomyopathy after radiofrequency ablation of incessant supraventricular tachycardia. Am Heart J. 1993;126:1469–73.PubMedCrossRef

71.

Leman RB, Gillette PC, Zinner AJ. Resolution of congestive cardiomyopathy caused by supraventricular tachycardia using amiodarone. Am Heart J. 1986;112:622–4.PubMedCrossRef

72.

Wu D, Denes P, Dhingra R, Pietras RJ, Rosen KM. New manifestations of dual A-V nodal pathways. Eur J Cardiol. 1975;2:459–66.PubMed

73.

• Wang NC. Dual atrioventricular nodal nonreentrant tachycardia: a systematic review. Pacing Clin Electrophysiol. 2011;34:1671–81. This is a recent systematic review of all reported cases of dual atrioventricular nodal nonreentrant tachycardia reporting the prevalence of tachycardia-induced cardiomyopathy as well as its response to treatment.PubMedCrossRef

74.

Anselme F, Boyle N, Josephson M. Incessant fascicular tachycardia: a cause of arrhythmia induced cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:760–3.PubMedCrossRef

75.

Vijgen J, Hill P, Biblo LA, Carlson MD. Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia. J Cardiovasc Electrophysiol. 1997;8:445–50.PubMedCrossRef

76.

Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol. 1996;19:1391–2.PubMedCrossRef

77.

• Hasdemir C, Ulucan C, Yavuzgil O, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol. 2011;22:663–8. This is a recent single center study reporting the prevalence of tachycardia-induced cardiomyopathy in patients presenting with premature ventricular contractions and/or ventricular tachycardia, as well as predictors of the development of tachycardia-induced cardiomyopathy.PubMedCrossRef

78.

Grimm W, Menz V, Hoffmann J, Maisch B. Reversal of tachycardia induced cardiomyopathy following ablation of repetitive monomorphic right ventricular outflow tract tachycardia. Pacing Clin Electrophysiol. 2001;24:166–71.PubMedCrossRef

79.

• Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7:865–9. This is a recent single center study of patients with frequent idiopathic premature ventricular contractions reporting the relationship to premature ventricular contraction burden and the development of tachycardia-induced cardiomyopathy.PubMedCrossRef

80.

Satish OS, Yeh KH, Wen MS, Wang CC. Premature ventricular contraction-induced concealed mechanical bradycardia and dilated cardiomyopathy. J Cardiovasc Electrophysiol. 2005;16:88–91.PubMedCrossRef

81.

Bogun F, Crawford T, Reich S, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007;4:863–7.PubMedCrossRef

82.

• Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm. 2011;8:1608–14. This is a single center study reporting the safety, efficacy, and long-term effect of catheter ablation of premature ventricular contractions on left ventricular dysfunction, as well as the impact of residual premature ventricular contractions on recovery of left ventricular function.PubMedCrossRef

83.

• Deyell MW, Park KM, Han Y, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular premature depolarizations. Heart Rhythm. 2012;9:1465–72. This is a recent single center study reporting predictors of recovery of left ventricular function following ablation of frequent premature ventricular contractions.PubMedCrossRef

84.

• Yokokawa M, Kim HM, Good E, et al. Impact of QRS duration of frequent premature ventricular complexes on the development of cardiomyopathy. Heart Rhythm. 2012;9:1460–4. This is a recent single center study evaluating the impact of QRS duration of frequent premature contractions on the development of cardiomyopathy.PubMedCrossRef

85.

• Yokokawa M, Good E, Crawford T, et al. Recovery from left ventricular dysfunction after ablation of frequent premature ventricular complexes. Heart Rhythm. 2013;10:172–5. This is a recent single center study reporting the time course and predictors of recovery of left ventricular dysfunction after ablation of premature ventricular contractions.PubMedCrossRef

86.

Hasdemir C, Musayev O, Kehribar DY, Kartal Y, Can LH. Chronic Cough and Tachycardia-Induced Cardiomyopathy in a Patient with Idiopathic Frequent, Monomorphic Premature Ventricular Contractions. Pacing Clin Electrophysiol. 2011;36:e156–8.

87.

• Del Carpio Munoz F, Syed FF, Noheria A, et al. Characteristics of premature ventricular complexes as correlates of reduced left ventricular systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J Cardiovasc Electrophysiol. 2011;22:791–8. This is a single center study reporting predictors of cardiomyopathy development in patients with frequent premature ventricular contractions.PubMedCrossRef

88.

Niwano S, Wakisaka Y, Niwano H, et al. Prognostic significance of frequent premature ventricular contractions originating from the ventricular outflow tract in patients with normal left ventricular function. Heart. 2009;95:1230–7.PubMedCrossRef

89.

Kanei Y, Friedman M, Ogawa N, Hanon S, Lam P, Schweitzer P. Frequent premature ventricular complexes originating from the right ventricular outflow tract are associated with left ventricular dysfunction. Ann Noninvasive Electrocardiol. 2008;13:81–5.PubMedCrossRef

90.

• Hasdemir C, Kartal Y, Simsek E, Yavuzgil O, Aydin M, Can LH. Time Course of Recovery of Left Ventricular Systolic Dysfunction in Patients with Premature Ventricular Contraction-Induced Cardiomyopathy. Pacing Clin Electrophysiol. 2013;36:612–7. This is a recent single center study reporting time course and degree of recovery of left ventricular dysfunction following treatment of arrhythmias based on echocardiographic characteristics.

91.

Jeong YH, Choi KJ, Song JM, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol. 2008;31:172–8.PubMedCrossRef

92.

Rabbani LE, Wang PJ, Couper GL, Friedman PL. Time course of improvement in ventricular function after ablation of incessant automatic atrial tachycardia. Am Heart J. 1991;121:816–9.PubMedCrossRef

93.

Lee SH, Chen SA, Tai CT, et al. Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation. J Am Coll Cardiol. 1998;31:637–44.PubMedCrossRef

94.

Dandamudi G, Rampurwala AY, Mahenthiran J, Miller JM, Das MK. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm. 2008;5:1111–4.PubMedCrossRef

95.

Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110:247–52.PubMedCrossRef

96.

Watanabe H, Okamura K, Chinushi M, et al. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J. 2008;49:39–47.PubMedCrossRef

97.

Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1290–5.PubMed

98.

Ilkhanoff L, Gerstenfeld EP, Zado ES, Marchlinski FE. Changes in ventricular dimensions and function during recovery of atrial tachycardia-induced cardiomyopathy treated with catheter ablation. J Cardiovasc Electrophysiol. 2007;18:1104–6.PubMedCrossRef

99.

Lacroix D, Gluais P, Marquie C, D'Hoinne C, Adamantidis M, Bastide M. Repolarization abnormalities and their arrhythmogenic consequences in porcine tachycardia-induced cardiomyopathy. Cardiovasc Res. 2002;54:42–50.PubMedCrossRef

100.

Pak PH, Nuss HB, Tunin RS, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol. 1997;30:576–84.PubMedCrossRef

Title: Heart Failure and Tachycardia-Induced Cardiomyopathy
Authors: Ethan R. Ellis
Mark E. Josephson
Publication date: 01-12-2013
Publisher: Springer US
Published in: Current Heart Failure Reports / Issue 4/2013
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI: https://doi.org/10.1007/s11897-013-0150-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers

Epidemiology and Importance of Renal Dysfunction in Heart Failure Patients

Epidemiology and Natural History of Recovery of Left Ventricular Function in Recent Onset Dilated Cardiomyopathies

Cardiac Metaiodobenzylguanidine Imaging and Heart Failure

Ventricular Remodeling in Heart Failure with Preserved Ejection Fraction

Prognostic Factors in Patients Hospitalized for Heart Failure

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage